GetTopicDetailResponse(id=42b311026e5f, topicName=瑞波替尼, introduction=瑞波替尼, content=NSCLC ROS1 瑞波替尼, image=null, comments=0, allHits=1083, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Fri Jan 19 11:10:35 CST 2024, time=2024-01-19, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=485982, tagList=[TagDto(tagId=485982, tagName=瑞波替尼)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2183078, encodeId=b9ad21830e824, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細胞肺癌#</a> <a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=42b311026e5f' target=_blank style='color:#2F92EE;'>#瑞波替尼#</a>, objectTitle=‘四大頂刊’一周研究導讀：國產(chǎn)小分子Simnotrelvir對新冠病毒具有良好的療效 ；瑞波替尼在ROS1融合陽性的NSCLC患者中顯示出持久的臨床活性；特瑞普利單抗聯(lián)合含鉑雙藥化療用于可手術II-III期非小細胞肺癌，EFS風險下了60%；, objectType=article, longId=810436, objectId=6ecf8104369e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221201/1669967638892_4754896.jpeg, objectUrl=/article/show_article.do?id=6ecf8104369e, replyNumber=0, likeNumber=147, createdTime=2024-01-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6ecf8104369e, moduleTitle=‘四大頂刊’一周研究導讀：國產(chǎn)小分子Simnotrelvir對新冠病毒具有良好的療效 ；瑞波替尼在ROS1融合陽性的NSCLC患者中顯示出持久的臨床活性；特瑞普利單抗聯(lián)合含鉑雙藥化療用于可手術II-III期非小細胞肺癌，EFS風險下了60%；, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6ecf8104369e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182600, encodeId=77172182600e3, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a> <a href='/topic/show?id=42b311026e5f' target=_blank style='color:#2F92EE;'>#瑞波替尼#</a>, objectTitle=NEJM：瑞波替尼在ROS1融合陽性非小細胞肺癌中的應用, objectType=article, longId=809978, objectId=db078099e850, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240118/1705584583628_6145188.png, objectUrl=/article/show_article.do?id=db078099e850, replyNumber=0, likeNumber=130, createdTime=2024-01-19, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=db078099e850, moduleTitle=NEJM：瑞波替尼在ROS1融合陽性非小細胞肺癌中的應用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=db078099e850)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-01-19發(fā)表于上海
